It’s 3 AM. You’re awake again, heart racing about nothing in particular, running through tomorrow’s to-do list while simultaneously catastrophizing about something that happened six years ago. If this sounds familiar, you’re not alone — and it may not be “just stress.”
Anxiety disorders are roughly twice as prevalent in women as in men. During perimenopause, the prevalence spikes further as estrogen fluctuations destabilize serotonin receptor sensitivity. Two peptides with published research relevant to anxiety and sleep — Selank and DSIP — offer mechanisms that work through pathways conventional medications don’t target.
Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics, Russian Academy of Sciences. It’s structurally related to tuftsin, a naturally occurring immunomodulatory peptide, and was designed to cross the blood-brain barrier.
Its primary mechanisms involve modulation of serotonin, dopamine, and GABA neurotransmitter signaling. Clinical studies in Russia have shown anxiolytic effects comparable to medazepam (a benzodiazepine), but with crucial differences: Selank also demonstrated antiasthenic effects (reducing fatigue), psychostimulant properties (improving alertness rather than causing sedation), nootropic benefits (enhancing memory and cognitive function), and immunomodulatory activity.
In a clinical study of 21 patients aged 18-45 with psychogenic anxiety disorders, intranasal Selank (0.15% drops, 900 mcg dose) produced anxiolytic effects within 30-40 minutes that lasted 6-12 hours. In 67% of patients, an initial tranquilizing effect reduced anxiety, emotional and muscular tension, restlessness, and fatigue while simultaneously improving activity and workability. In 71% of patients, symptoms reduced significantly within the first days of therapy.
Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring nonapeptide first isolated from rabbit cerebral blood in 1977. Its name comes from early findings that it increased delta-wave activity on EEG — the brainwave pattern corresponding to deep, restorative sleep.
DSIP has been found in the hypothalamus, limbic system, pituitary, and various peripheral tissues. It co-localizes with multiple hormones and neurotransmitters, suggesting broad regulatory functions beyond just sleep. The mental health relevance is indirect but significant: if DSIP genuinely improves sleep quality, the downstream effects on mood, cognition, and stress resilience are substantial. Sleep is foundational to everything.
Typical protocols start at 100-250 mcg nightly under medical guidance. DSIP is not FDA-approved and clinical evidence remains limited compared to conventional sleep medications.
BPC-157’s relevance to anxiety may seem surprising, but the gut-brain axis is increasingly recognized as a major player in mood regulation. BPC-157 modulates dopamine and serotonin systems while protecting neurons from stress-related damage. For women whose anxiety co-occurs with digestive issues (a common pattern, especially with IBS, which is twice as common in women as men), BPC-157 may address both the gut and mood components.
| Goal | Primary Peptide | Supporting | Notes |
|---|---|---|---|
| Daytime anxiety | Selank (100-300 mcg intranasal) | NAD+ for energy | Morning dosing; effects last 6-12 hours |
| Nighttime anxiety / racing thoughts | Selank + DSIP | — | Selank calms; DSIP promotes deep sleep |
| Anxiety + gut issues | Selank + BPC-157 | KPV if autoimmune | Addresses gut-brain axis |
| Sleep disruption only | DSIP (100-250 mcg) | CJC-1295/Ipa before bed | GH secretagogue enhances deep sleep phases |
| Brain fog + fatigue + mood | NAD+ + Selank | CJC-1295/Ipa | Mitochondrial energy + neuropeptide support |
Clinical studies found Selank's anxiolytic effects comparable to medazepam (a benzodiazepine). However, Selank works through different pathways — modulating serotonin, dopamine, and GABA without the sedation, cognitive impairment, or dependence risk associated with benzodiazepines. Selank is clinically used in Russia but is not FDA-approved in the United States.
DSIP enhances delta-wave sleep activity, which corresponds to deep, restorative sleep — exactly what perimenopause disrupts. It's a naturally occurring neuropeptide first identified in the 1970s. Clinical evidence is limited compared to conventional sleep medications, but the mechanistic rationale is sound. Work with a provider experienced in peptide sleep protocols.
Peptides that modulate serotonin, dopamine, or GABA (like Selank) could theoretically interact with SSRIs, SNRIs, or benzodiazepines. Always discuss peptide therapy with the provider managing your psychiatric medications. Never stop prescribed medications to try peptides.
Anxiety disorders are approximately twice as prevalent in women as in men. Hormonal fluctuations (menstrual cycle, pregnancy, perimenopause) directly affect neurotransmitter systems. Estrogen modulates serotonin receptor sensitivity, so when estrogen levels fluctuate during perimenopause, anxiety often intensifies — even in women with no prior history.